Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, dose-tolerability titration study to evaluate the efficacy and safety of perampanel (E2007) in patients with post-herpetic neuralgia (PHN).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 07 May 2012 Actual patient number added 135 according to ClinicalTrials.gov.
- 12 Aug 2009 Additional location identified as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.